Clinical trial · Observational
Molecular Characterisation of Colorectal Cancer Peritoneal Metastases
Molecular Characterisation of Colorectal Cancer Peritoneal Metastases: Genomic and Transcriptomic Analysis With Correlation of Clinical Outcomes
NCT05513716CI-TRIAL-00084279COLOMET IIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project aims to characterise the tumour cell and tumour microenvironment of colorectal cancer peritoneal metastases, understand molecular changes leading to colorectal peritoneal metastasis, identify potential biomarkers and novel treatment strategies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Retrospective tissue sample analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All patients
- description
- Colorectal cancer patients
- interventionNames
- Other: Retrospective tissue sample analysis
Primary outcomes (1)
- measure
- Proportion of genetic mutations
- timeFrame
- 24 months
- description
- Descriptive analysis of the proportion of genetic mutations identified in colorectal cancer and their matched peritoneal metastases: concordance and discordance rates.
Secondary outcomes (3)
- measure
- Proportion differences of genetic mutations
- timeFrame
- 24 months
- description
- The descriptive difference in proportion of genetic mutations identified in primary colorectal tumours compared to mutations in colorectal cancer peritoneal metastases. Generate hypotheses about changes that occur during the metastatic process.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Participants are eligible to be included in the study only if all of the following criteria apply: 1. Patients ≥ 18 years old who have been diagnosed with colorectal cancer and have colorectal peritoneal metastases, 2. have had cytoreductive surgery at the Christie 3. have availability of archival tumour tissue (paired CRC and CRPM) Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.